{"entity":{"id":"nct06888674","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","aka":[],"tldr":"A phase 1/2 trial of gemcitabine, capecitabine and sintilimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.","summary":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. is a phase 1/2, interventional study registered as NCT06888674 by Zhejiang University, with a registry enrolment figure of 60 participants, started 2025-04-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: individualized anti-tumor new antigen iNeo-Vac-R01 injection; Gemcitabine + Capecitabine; Sintilimab injection. Conditions listed: Pancreatic Cancer Resectable. Primary outcome: Occurence and frequence of AE and SAE. Pancreatic eligibility wording from the registry: \"* Diagnosed with resectable pancreatic cancer as assessed per the 2024 NCCN Clinical Practice Guidelines and willing to undergo radical surgery;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06888674","url":"https://clinicaltrials.gov/study/NCT06888674"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine","capecitabine","sintilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06888674","phase":"1/2","setting":"Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen MRNA Therapy Combined with PD-1 Antibody and Chemotherapy As Adjuvant Treatment for Postoperative Pancreatic Cancer.","sponsor":"Zhejiang University","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06888674/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}